PH12020550461A1 - Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides - Google Patents
Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptidesInfo
- Publication number
- PH12020550461A1 PH12020550461A1 PH12020550461A PH12020550461A PH12020550461A1 PH 12020550461 A1 PH12020550461 A1 PH 12020550461A1 PH 12020550461 A PH12020550461 A PH 12020550461A PH 12020550461 A PH12020550461 A PH 12020550461A PH 12020550461 A1 PH12020550461 A1 PH 12020550461A1
- Authority
- PH
- Philippines
- Prior art keywords
- visceral fat
- sfgfr3
- polypeptides
- fat deposition
- treatment
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 3
- 230000008021 deposition Effects 0.000 title abstract 3
- 210000001596 intra-abdominal fat Anatomy 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 title 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561140P | 2017-09-20 | 2017-09-20 | |
| PCT/EP2018/075471 WO2019057820A1 (en) | 2017-09-20 | 2018-09-20 | ABNORMAL VISCERAL GREASE DEPOSITION TREATMENT USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020550461A1 true PH12020550461A1 (en) | 2021-03-22 |
Family
ID=63878625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020550461A PH12020550461A1 (en) | 2017-09-20 | 2020-04-20 | Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200297799A1 (enExample) |
| EP (1) | EP3684394A1 (enExample) |
| JP (1) | JP7335247B2 (enExample) |
| KR (1) | KR20200103621A (enExample) |
| CN (1) | CN111836634A (enExample) |
| AU (1) | AU2018335837A1 (enExample) |
| BR (1) | BR112020005459A2 (enExample) |
| CA (1) | CA3076396A1 (enExample) |
| IL (1) | IL273203A (enExample) |
| MX (1) | MX2020003114A (enExample) |
| PH (1) | PH12020550461A1 (enExample) |
| WO (1) | WO2019057820A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150344855A1 (en) | 2013-01-16 | 2015-12-03 | INSERM (Institut National de la Santé et de la Recherche Médicale | A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders |
| KR102432192B1 (ko) | 2016-07-07 | 2022-08-12 | 화이자 인코포레이티드 | 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도 |
| NL2020176B1 (en) * | 2017-12-22 | 2019-07-02 | Van Der Hoeven Horticultural Projects B V | Greenhouse |
| CN110272900B (zh) * | 2019-04-19 | 2024-03-26 | 中国人民解放军陆军军医大学 | 用于制备骨骼发育异常猪模型的sgRNA及其应用 |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| JP2022184798A (ja) | 2021-06-01 | 2022-12-13 | ファイザー・インク | ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法 |
| WO2024147597A1 (ko) * | 2023-01-03 | 2024-07-11 | 서울대학교산학협력단 | Fgfr3 발현 또는 활성 억제제의 퇴행성 신경질환 치료 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040109850A1 (en) * | 2000-12-18 | 2004-06-10 | Neelam Jaiswal | Treatment of bone disorders by modulation of fgfr3 |
| US20150344855A1 (en) * | 2013-01-16 | 2015-12-03 | INSERM (Institut National de la Santé et de la Recherche Médicale | A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders |
| RS60593B1 (sr) * | 2014-01-24 | 2020-08-31 | Ngm Biopharmaceuticals Inc | Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu |
| CA2972865A1 (en) * | 2015-01-07 | 2016-07-14 | Therachon Sas | Soluble fgfr3 decoys for treating skeletal growth disorders |
| KR102432192B1 (ko) * | 2016-07-07 | 2022-08-12 | 화이자 인코포레이티드 | 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도 |
-
2018
- 2018-09-20 EP EP18788669.2A patent/EP3684394A1/en not_active Withdrawn
- 2018-09-20 KR KR1020207009844A patent/KR20200103621A/ko not_active Ceased
- 2018-09-20 JP JP2020537858A patent/JP7335247B2/ja active Active
- 2018-09-20 WO PCT/EP2018/075471 patent/WO2019057820A1/en not_active Ceased
- 2018-09-20 AU AU2018335837A patent/AU2018335837A1/en not_active Abandoned
- 2018-09-20 CN CN201880061038.6A patent/CN111836634A/zh active Pending
- 2018-09-20 CA CA3076396A patent/CA3076396A1/en active Pending
- 2018-09-20 US US16/649,208 patent/US20200297799A1/en not_active Abandoned
- 2018-09-20 BR BR112020005459-3A patent/BR112020005459A2/pt not_active IP Right Cessation
- 2018-09-20 MX MX2020003114A patent/MX2020003114A/es unknown
-
2020
- 2020-03-10 IL IL273203A patent/IL273203A/en unknown
- 2020-04-20 PH PH12020550461A patent/PH12020550461A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3684394A1 (en) | 2020-07-29 |
| WO2019057820A1 (en) | 2019-03-28 |
| AU2018335837A1 (en) | 2020-04-23 |
| BR112020005459A2 (pt) | 2020-09-29 |
| JP2020534367A (ja) | 2020-11-26 |
| IL273203A (en) | 2020-04-30 |
| US20200297799A1 (en) | 2020-09-24 |
| RU2020113712A3 (enExample) | 2022-01-14 |
| JP7335247B2 (ja) | 2023-08-29 |
| MX2020003114A (es) | 2020-10-20 |
| KR20200103621A (ko) | 2020-09-02 |
| CN111836634A (zh) | 2020-10-27 |
| CA3076396A1 (en) | 2019-03-28 |
| RU2020113712A (ru) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003114A (es) | Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3). | |
| ZA201903327B (en) | Compositions and methods for the induction of cd8+ t¿cells | |
| SG11202104501UA (en) | Systems and methods for the treatment of eye conditions | |
| SG10201809427SA (en) | Insulin receptor partial agonists | |
| MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
| SI3658140T1 (sl) | Kombinacije aprocitentana z nadaljnjimi učinkovinami za zdravljenje rezistentne hipertenzije | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| SV2018005614A (es) | Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias | |
| MY208231A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| SMT202400071T1 (it) | Oligomeri antisenso per il trattamento di condizioni e malattie | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| PH12020550255A1 (en) | Treatment of smc mediated disease | |
| PH12019501534A1 (en) | Csf1r-based chimeric proteins | |
| MX2018003536A (es) | Metodos para el tratamiento de la epilepsia. | |
| IL277557A (en) | Self-assembling peptidomimetics and peptidomimetics for the treatment of eye diseases | |
| PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
| EP4275746A3 (en) | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use | |
| IL275349A (en) | Use of hM4Di in the treatment of seizure disorders | |
| IL274838A (en) | Use of MIR101 or MIR128 in the treatment of seizure disorders | |
| GB201614415D0 (en) | Enzymes for the treatment of human enterometabolic dysfunction | |
| ZA202105101B (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
| GB2574747A (en) | Use of lambda interferons in the treatment of obesity-related disorders and related diseases |